This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform
by Zacks Equity Research
Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.
Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA
by Zacks Equity Research
Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.
McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group
by Zacks Equity Research
McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.
Is Universal Health Services (UHS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stryker's (SYK) Gamma4 Expansion Set to Boost Fracture Healing
by Zacks Equity Research
With the expansion of Gamma4, Stryker (SYK) is looking forward to strengthening its nailing system and solidifying its position as a leading choice in Orthopedic procedures.
PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction
by Zacks Equity Research
PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.
Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency
by Zacks Equity Research
Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools
by Zacks Equity Research
GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.
Why Fast-paced Mover Universal Health Services (UHS) Is a Great Choice for Value Investors
by Zacks Equity Research
Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare Company and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare Company and Community Health Systems are part of the Zacks Industry Outlook article.
5 Hospital Stocks to Watch Amid Promising Industry Trends
by Kaibalya Pravo Dey
Rising patient volumes and technological advancements for the Zacks Medical-Hospital industry players are major positives. HCA, UHS, THC, ACHC and CYH are poised to gain from improving operating efficiency.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Universal Health Services (UHS) Up 11.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna (CI) Q3 Earnings Beat on Membership Growth, '23 EPS View Up
by Zacks Equity Research
Cigna's (CI) Q3 results benefit on well-performing U.S. Commercial and Medicare Advantage businesses. Management currently expects 2023 adjusted EPS to be a minimum of $24.75.
Encompass Health's (EHC) Q3 Earnings Beat on Discharge Growth
by Zacks Equity Research
Encompass Health's (EHC) Q3 results benefit from an increase in patient volumes and net patient revenue per discharge. Management currently projects adjusted EPS to be within $3.41-$3.52 for 2023.
Universal Health (UHS) Q3 Earnings Beat on Adjusted Patient Days
by Zacks Equity Research
Universal Health (UHS) has a leftover repurchase capacity of around $580 million as of Sep 30, 2023.
Universal Health Services (UHS) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Universal Health Services (UHS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Universal Health Services (UHS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 8.97% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Tenet Healthcare (THC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.